1. Home
  2. FLYX vs RNTX Comparison

FLYX vs RNTX Comparison

Compare FLYX & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo flyExclusive Inc.

FLYX

flyExclusive Inc.

HOLD

Current Price

$2.16

Market Cap

97.7M

Sector

Finance

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.88

Market Cap

80.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLYX
RNTX
Founded
2015
2001
Country
United States
United States
Employees
N/A
10
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.7M
80.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FLYX
RNTX
Price
$2.16
$0.88
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
337.5K
579.9K
Earning Date
05-13-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.47
N/A
Revenue Next Year
$15.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.88
$0.85
52 Week High
$8.88
$2.18

Technical Indicators

Market Signals
Indicator
FLYX
RNTX
Relative Strength Index (RSI) 42.26 38.81
Support Level $1.97 N/A
Resistance Level $2.81 $1.33
Average True Range (ATR) 0.19 0.08
MACD -0.05 0.00
Stochastic Oscillator 23.38 24.33

Price Performance

Historical Comparison
FLYX
RNTX

About FLYX flyExclusive Inc.

flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet, which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: